| Sarah Case, MD | |
|
593 Eddy St, Claverick 2, Providence, RI 02903-4923 | |
| (401) 519-1604 | |
| (401) 272-0538 |
| Full Name | Sarah Case |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Emergency Medicine |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184734659 | NPI | - | NPPES |
| 0070588631 | Other | RI | RI MEDICARE |
| 07012011 | Other | MA | TUFTS HEALTH PLAN |
| 07012011 | Other | RI | UNITED HEALTHCARE |
| 7058863 | Medicaid | RI | |
| 939025129 | Other | RI | RI MEDICARE GROUP NUMBER |
| 110074069/A | Medicaid | MA | |
| 1184734659 | Other | RI | NPI |
| 08112011 | Other | RI | NHPRI |
| 07232011 | Other | RI | BCBSRI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD11848 (Rhode Island) | Secondary |
| 2080P0204X | Pediatrics - Pediatric Emergency Medicine | MD11848 (Rhode Island) | Primary |
| Entity Name | Brown Emergency Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962455022 PECOS PAC ID: 7214833169 Enrollment ID: O20040116000868 |
News Archive
The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it has submitted a plan advising the NYSE Amex of the actions it has taken and will take to bring the Company into compliance with certain listing standards of the NYSE Amex by February 17, 2012.
The NIH has reported that many individuals with COVID-19 develop abnormal blood clots from high inflammation, which can lead to serious health complications and mortality.
The St. Louis Beacon reports that the legislature might take up a bill Friday that strips controversial provisions passed by the House earlier in the week.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.
› Verified 9 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it has submitted a plan advising the NYSE Amex of the actions it has taken and will take to bring the Company into compliance with certain listing standards of the NYSE Amex by February 17, 2012.
The NIH has reported that many individuals with COVID-19 develop abnormal blood clots from high inflammation, which can lead to serious health complications and mortality.
The St. Louis Beacon reports that the legislature might take up a bill Friday that strips controversial provisions passed by the House earlier in the week.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Case, MD Po Box 9484, Providence, RI 02940-9484 Ph: (401) 854-2508 | Sarah Case, MD 593 Eddy St, Claverick 2, Providence, RI 02903-4923 Ph: (401) 519-1604 |
News Archive
The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it has submitted a plan advising the NYSE Amex of the actions it has taken and will take to bring the Company into compliance with certain listing standards of the NYSE Amex by February 17, 2012.
The NIH has reported that many individuals with COVID-19 develop abnormal blood clots from high inflammation, which can lead to serious health complications and mortality.
The St. Louis Beacon reports that the legislature might take up a bill Friday that strips controversial provisions passed by the House earlier in the week.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.
› Verified 9 days ago
Evianna Cruz Herrera, MD/MPH Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903 Phone: 401-444-4471 | |
Sara Regan Ford, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1 Hoppin St, Coro Center Suite 304, Providence, RI 02903 Phone: 401-444-4612 Fax: 401-793-8831 | |
Jennifer F Friedman, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Lower Level, Providence, RI 02903 Phone: 401-444-4471 Fax: 401-444-3870 | |
Jason Shapiro, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 | |
Dr. Mikhaela Monty, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-4471 Fax: 401-444-7574 | |
Dale Steele, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Claverick 2, Providence, RI 02903 Phone: 401-854-2504 Fax: 401-854-2519 | |
Chase B Samsel, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 |